Repositioning canakinumab for non-small cell lung cancer-important lessons for drug repurposing in oncology

Related Experiment Video

Updated: Sep 6, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K

Mark P Lythgoe1, Vinay Prasad2

  • 1Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0HS, UK. M.Lythgoe@imperial.ac.uk.

British Journal of Cancer
|June 23, 2022
PubMed

Insights

Canakinumab, an anti-interleukin-1β therapy, showed promise in reducing lung cancer in a cardiovascular trial. However, subsequent oncology trials (CANOPY-1 and 2) failed to meet primary efficacy endpoints, impacting cancer drug repurposing strategies.

Area of Science:

  • Oncology
  • Immunology
  • Drug Repurposing

Background:

  • Canakinumab (anti-interleukin-1β) is approved for immune-related disorders.
  • The CANTOS trial observed reduced lung cancer incidence and mortality with canakinumab.
  • This led to trials investigating canakinumab for cancer treatment.

Purpose of the Study:

  • To explore the rationale for developing canakinumab in oncology.
  • To analyze the drug repurposing approach for canakinumab in cancer therapy.
  • To discuss the implications for future cancer drug development.

Main Methods:

  • Review of scientific and clinical rationale for canakinumab in oncology.
  • Analysis of the drug repurposing strategy.
  • Evaluation of reported clinical trial outcomes (CANOPY-1 and 2).

Main Results:

  • Canakinumab demonstrated an unexpected reduction in lung cancer in the CANTOS trial.
  • The CANOPY-1 and CANOPY-2 trials did not meet their primary efficacy endpoints.
  • The initial promising signal for canakinumab in lung cancer was not validated.

Conclusions:

  • The development of canakinumab in oncology, based on initial observations, faced setbacks.
  • The failure of CANOPY-1 and 2 highlights challenges in drug repurposing for cancer.
  • This case study offers insights into the complexities of developing new cancer medicines through repurposed drugs.

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.1K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K